TRIM21 and myositis disease: Previous studies indicate that anti-Ro52 antibodies are frequently associated with various myositis-specific autoantibodies (MSAs)–including anti-tRNA synthetase antibodies—and that the coexistence of MSAs and anti-Ro52 antibodies may portend worse clinical outcomes.